Published in Clin Auton Res on December 01, 1998
Evaluation of Primary Chronic Autonomic Failure | NCT00059033
SNCA variants are associated with increased risk for multiple system atrophy. Ann Neurol (2009) 3.55
Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study. Brain (2008) 1.72
Biomarkers to detect central dopamine deficiency and distinguish Parkinson disease from multiple system atrophy. Parkinsonism Relat Disord (2008) 1.49
Feasibility of [18F]-2-Fluoro-A85380-PET imaging of human vascular nicotinic acetylcholine receptors in vivo. JACC Cardiovasc Imaging (2012) 1.48
Noninvasive detection of sympathetic neurocirculatory failure. Clin Auton Res (2000) 1.45
Peripheral neuropathy as the presenting feature of multiple system atrophy. Clin Auton Res (2001) 1.39
Incidence and pathology of synucleinopathies and tauopathies related to parkinsonism. JAMA Neurol (2013) 1.32
Autopsy confirmed multiple system atrophy cases: Mayo experience and role of autonomic function tests. J Neurol Neurosurg Psychiatry (2012) 1.29
The alpha-synuclein gene in multiple system atrophy. J Neurol Neurosurg Psychiatry (2006) 1.25
Multiple system atrophy: a clinical and neuropathological perspective. Trends Neurosci (2011) 1.18
Differentiating multiple system atrophy from Parkinson's disease: contribution of striatal and midbrain MRI volumetry and multi-tracer PET imaging. J Neurol Neurosurg Psychiatry (2002) 1.13
Olfactory dysfunction in pure autonomic failure: Implications for the pathogenesis of Lewy body diseases. Parkinsonism Relat Disord (2009) 1.08
The European Multiple System Atrophy-Study Group (EMSA-SG). J Neural Transm (Vienna) (2005) 1.05
Accuracy and sensitivity of Parkinsonian disorder diagnoses in two Swedish national health registers. Neuroepidemiology (2012) 1.05
Utility of susceptibility-weighted MRI in differentiating Parkinson's disease and atypical parkinsonism. Neuroradiology (2010) 1.03
Recent developments in multiple system atrophy. J Neurol (2009) 1.00
Incidence and time trends of drug-induced parkinsonism: A 30-year population-based study. Mov Disord (2016) 0.99
Towards translational therapies for multiple system atrophy. Prog Neurobiol (2014) 0.98
Dysautonomia in Parkinson disease. Compr Physiol (2014) 0.95
Identification of circulating microRNAs for the differential diagnosis of Parkinson's disease and Multiple System Atrophy. Front Cell Neurosci (2014) 0.92
Comprehensive autonomic assessment does not differentiate between Parkinson's disease, multiple system atrophy and progressive supranuclear palsy. J Neural Transm (Vienna) (2009) 0.90
Summary of cerebrospinal fluid routine parameters in neurodegenerative diseases. J Neurol (2010) 0.90
Clinical and physiological characteristics of autonomic failure with Parkinson's disease. Clin Auton Res (1999) 0.89
Tauopathies and synucleinopathies: do cerebrospinal fluid beta-amyloid peptides reflect disease-specific pathogenesis? J Neural Transm (Vienna) (2007) 0.87
Time Trends in the Incidence of Parkinson Disease. JAMA Neurol (2016) 0.87
Cognition in multiple system atrophy: neuropsychological profile and interaction with mood. J Neural Transm (Vienna) (2010) 0.86
Skin vasomotor reflex responses in two contrasting groups of autonomic failure: multiple system atrophy and pure autonomic failure. J Neurol (2006) 0.86
The effects of water ingestion on orthostatic hypotension in two groups of chronic autonomic failure: multiple system atrophy and pure autonomic failure. J Neurol Neurosurg Psychiatry (2004) 0.84
Prevalence of REM sleep behavior disorder in multiple system atrophy: a multicenter study and meta-analysis. Clin Auton Res (2015) 0.83
Valsalva manoeuvre in patients with different Parkinsonian disorders. J Neural Transm (Vienna) (2009) 0.83
Feasibility of 2-deoxy-2-[18F]fluoro-D-glucose- A85380-PET for imaging of human cardiac nicotinic acetylcholine receptors in vivo. Clin Res Cardiol (2006) 0.82
PRNP M129V homozygosity in multiple system atrophy vs. Parkinson's disease. Clin Auton Res (2008) 0.82
The cold hand sign in multiple system atrophy: skin perfusion revisited. J Neural Transm (Vienna) (2010) 0.80
Assessment of cardiovascular autonomic dysfunction in multiple system atrophy. Clin Auton Res (2001) 0.79
Models of multiple system atrophy. Curr Top Behav Neurosci (2015) 0.79
Characteristic signal changes in the pontine base on T2- and multishot diffusion-weighted images in spinocerebellar ataxia type 1. Neuroradiology (2005) 0.79
Periodic leg movements in sleep in elderly patients with Parkinsonism and Alzheimer's disease. Eur J Neurol (2012) 0.79
Usefulness of 3D-PRESTO imaging in evaluating putaminal abnormality in parkinsonian variant of multiple system atrophy. Neuroradiology (2009) 0.78
Differences in overshoot of blood pressure after head-up tilt in two groups with chronic autonomic failure: pure autonomic failure and multiple system atrophy. J Neurol (2005) 0.77
Cardiac ectopy in chronic autonomic failure. Clin Auton Res (2009) 0.77
Signal alterations of the basal ganglia in the differential diagnosis of Parkinson's disease: a retrospective case-controlled MRI data bank analysis. BMC Neurol (2012) 0.76
Event-related desynchronization of motor cortical oscillations in patients with multiple system atrophy. Exp Brain Res (2010) 0.76
Neuroendocrine and behavioural responses to CO2 inhalation in central versus peripheral autonomic failure. Clin Auton Res (2006) 0.76
Comparison of Cerebral Glucose Metabolism between Possible and Probable Multiple System Atrophy. J Mov Disord (2009) 0.76
A novel computer-assisted image analysis of [123I]β-CIT SPECT images improves the diagnostic accuracy of parkinsonian disorders. Eur J Nucl Med Mol Imaging (2010) 0.75
Diagnosis and differential diagnosis of MSA: boundary issues. J Neurol (2015) 0.75
A new sign of sympathetic neurocirculatory failure: premature ventricular contraction as a "one-beat Valsalva maneuver". Clin Auton Res (2000) 0.75
Cardiovascular autonomic functions & cerebral autoregulation in patients with orthostatic hypotension. Indian J Med Res (2011) 0.75
Residual sympathetic tone is associated with reduced insulin sensitivity in patients with autonomic failure. Clin Auton Res (2015) 0.75
Lack of autonomic nervous dysfunction in progressive supranuclear palsy, a study of blood pressure variability. Clin Auton Res (2000) 0.75
Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology (1996) 8.82
Composite autonomic scoring scale for laboratory quantification of generalized autonomic failure. Mayo Clin Proc (1993) 3.40
Orthostatic hypotension and nicotine sensitivity in a case of multiple system atrophy. J Neurol Neurosurg Psychiatry (1969) 2.89
Clinical features and natural history of multiple system atrophy. An analysis of 100 cases. Brain (1994) 2.77
Clinical usefulness of magnetic resonance imaging in multiple system atrophy. J Neurol Neurosurg Psychiatry (1998) 2.19
The natural history of degenerative ataxia: a retrospective study in 466 patients. Brain (1998) 2.11
Genitourinary dysfunction in multiple system atrophy: clinical features and treatment in 62 cases. J Urol (1994) 1.55
Autonomic involvement in extrapyramidal and cerebellar disorders. Clin Auton Res (1991) 1.44
Multiple system atrophy: natural history, MRI morphology, and dopamine receptor imaging with 123IBZM-SPECT. J Neurol Neurosurg Psychiatry (1994) 1.41
What is the accuracy of the clinical diagnosis of multiple system atrophy? A clinicopathologic study. Arch Neurol (1997) 1.35
The dopaminergic response in multiple system atrophy. J Neurol Neurosurg Psychiatry (1992) 1.27
Value of sphincter electromyography in the diagnosis of multiple system atrophy. Muscle Nerve (1997) 1.15
Multiple system atrophy presenting as parkinsonism: clinical features and diagnostic criteria. J Neurol Neurosurg Psychiatry (1995) 0.96
Multiple system atrophy. Clinical and MR observations on 42 cases. Ital J Neurol Sci (1993) 0.90
Striatonigral degeneration: iron deposition in putamen correlates with the slit-like void signal of magnetic resonance imaging. Can J Neurol Sci (1994) 0.86
Characteristics of the dysarthria of multiple system atrophy. Arch Neurol (1996) 0.85
Response to L-DOPA in multiple system atrophy. Clin Neuropharmacol (1993) 0.77
Autonomic dysfunction. Br J Hosp Med (1987) 0.76
Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology (2005) 21.67
The same prion strain causes vCJD and BSE. Nature (1997) 12.49
Diagnostic criteria for Parkinson disease. Arch Neurol (1999) 11.65
Gibberellins and Light Inhibition of Stem Growth in Peas. Plant Physiol (1964) 11.01
Social deprivation and premature mortality: regional comparison across England. BMJ (1993) 9.74
The FAB: a Frontal Assessment Battery at bedside. Neurology (2000) 8.93
Second consensus statement on the diagnosis of multiple system atrophy. Neurology (2008) 7.27
Life course epidemiology. J Epidemiol Community Health (2003) 6.75
Scale for the assessment and rating of ataxia: development of a new clinical scale. Neurology (2006) 6.44
Effect of some (2-chloroethyl) trimethylammonium chloride analogs and other growth retardants on gibberellin biosynthesis in Fusarium moniliforme. Plant Physiol (1965) 6.08
What features improve the accuracy of clinical diagnosis in Parkinson's disease: a clinicopathologic study. Neurology (1992) 6.03
Chloroplast transformation in Chlamydomonas with high velocity microprojectiles. Science (1988) 5.91
Evidence for Substances in Higher Plants Interfering with Response of Dwarf Peas to Gibberellin. Plant Physiol (1963) 5.86
Fate of radioactive gibberellin a(1) in maturing and germinating seeds of peas and Japanese morning glory. Plant Physiol (1968) 5.73
Lettuce Seed Germination: Evidence for a Reversible Light-Induced Increase in Growth Potential and for Phytochrome Mediation of the Low Temperature Effect. Plant Physiol (1965) 5.73
Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA (2005) 5.60
Consensus statement on the diagnosis of multiple system atrophy. J Neurol Sci (1999) 5.01
What contributes to quality of life in patients with Parkinson's disease? J Neurol Neurosurg Psychiatry (2000) 4.66
Expression of the CD34 gene in vascular endothelial cells. Blood (1990) 4.41
Bilateral deep brain stimulation in Parkinson's disease: a multicentre study with 4 years follow-up. Brain (2005) 4.33
Preliminary NINDS neuropathologic criteria for Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy). Neurology (1994) 4.24
Association of an extended haplotype in the tau gene with progressive supranuclear palsy. Hum Mol Genet (1999) 4.17
Extractable and Diffusible Gibberellins From Light- and Dark-grown Pea Seedlings. Plant Physiol (1968) 4.02
Prevalence of progressive supranuclear palsy and multiple system atrophy: a cross-sectional study. Lancet (1999) 3.94
Frailty in elderly people: an evolving concept. CMAJ (1994) 3.84
The Emerging Risk Factors Collaboration: analysis of individual data on lipid, inflammatory and other markers in over 1.1 million participants in 104 prospective studies of cardiovascular diseases. Eur J Epidemiol (2007) 3.81
A comparison of injections of botulinum toxin and topical nitroglycerin ointment for the treatment of chronic anal fissure. N Engl J Med (1999) 3.69
A clinicopathological study of autism. Brain (1998) 3.49
Immune response-associated production of neopterin. Release from macrophages primarily under control of interferon-gamma. J Exp Med (1984) 3.31
A comparison of botulinum toxin and saline for the treatment of chronic anal fissure. N Engl J Med (1998) 3.19
Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD. Neurology (2008) 3.10
Office of Rare Diseases neuropathologic criteria for corticobasal degeneration. J Neuropathol Exp Neurol (2002) 3.02
A potent pressor response elicited by drinking water. Lancet (1999) 3.02
A novel lymphotropic herpesvirus. Lancet (1987) 2.89
The neuropathic postural tachycardia syndrome. N Engl J Med (2000) 2.86
Dose standardisation of botulinum toxin. Lancet (1989) 2.83
Counting the cost of social disadvantage in primary care: retrospective analysis of patient data. BMJ (1997) 2.82
Geminiviruses: models for plant DNA replication, transcription, and cell cycle regulation. Crit Rev Biochem Mol Biol (2000) 2.72
The phenotypic spectrum of CADASIL: clinical findings in 102 cases. Ann Neurol (1998) 2.72
Autosomal dominant "Opitz" GBBB syndrome due to a 22q11.2 deletion. Am J Med Genet (1995) 2.70
A new stress-related syndrome of growth failure and hyperphagia in children, associated with reversibility of growth-hormone insufficiency. Lancet (1996) 2.58
Physiological effects of gibberellic acid. 8. Growth retardants on barley endosperm. Plant Physiol (1965) 2.58
Orthostatic intolerance and tachycardia associated with norepinephrine-transporter deficiency. N Engl J Med (2000) 2.53
Effects of caffeine on plasma renin activity, catecholamines and blood pressure. N Engl J Med (1978) 2.50
Observations on recurrent syncope and presyncope in 641 patients. Lancet (2001) 2.49
Structural brain abnormalities associated with deletion at chromosome 22q11: quantitative neuroimaging study of adults with velo-cardio-facial syndrome. Br J Psychiatry (2001) 2.49
How valid is the clinical diagnosis of Parkinson's disease in the community? J Neurol Neurosurg Psychiatry (2002) 2.48
Ultrastructural localization of bcl-2 protein. J Histochem Cytochem (1992) 2.48
Blepharospasm: a review of 264 patients. J Neurol Neurosurg Psychiatry (1988) 2.46
Differing patterns of striatal 18F-dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Ann Neurol (1990) 2.45
Consensus statement on the definition of orthostatic hypotension, pure autonomic failure and multiple system atrophy. Clin Auton Res (1996) 2.40
Inhibition of cell division and cell elongation in higher plants by inhibitors of DNA synthesis. Dev Biol (1965) 2.38
Streptococcal infection, Tourette syndrome, and OCD: is there a connection? Neurology (2009) 2.33
Parkinson's disease is associated with oxidative damage to cytoplasmic DNA and RNA in substantia nigra neurons. Am J Pathol (1999) 2.31
Validity of current clinical criteria for Alzheimer's disease, vascular dementia and dementia with Lewy bodies. Br J Psychiatry (1999) 2.31
Yohimbine: a pharmacological probe for study of the alpha 2-adrenoreceptor. Pharmacol Rev (1983) 2.30
A single bone marrow-derived stromal cell type supports the in vitro growth of early lymphoid and myeloid cells. Cell (1987) 2.27
Apathy is not depression. J Neuropsychiatry Clin Neurosci (1998) 2.24
New approach in strabismus surgery in high myopia. Br J Ophthalmol (1997) 2.23
How does Parkinson's disease affect quality of life? A comparison with quality of life in the general population. Mov Disord (2000) 2.23
Contents and recovery of gibberellins in monoecious and gynoecious cucumber plants. Plant Physiol (1968) 2.20
Molecular genetic alterations in glioblastomas with oligodendroglial component. Acta Neuropathol (2001) 2.17
Optimum method for administration of biosynthetic human growth hormone: a randomised crossover trial of an Auto Injector and a pen injection system. Arch Dis Child (1992) 2.17
Cross sectional prevalence survey of idiopathic Parkinson's disease and Parkinsonism in London. BMJ (2000) 2.17
Haplotypes and gene expression implicate the MAPT region for Parkinson disease: the GenePD Study. Neurology (2008) 2.16
Management of Parkinson's disease a review of current and new therapies. Can J Neurol Sci (1999) 2.16
Equity in the NHS. Monitoring and promoting equity in primary and secondary care. BMJ (1994) 2.13
Gene silencing from plant DNA carried by a Geminivirus. Plant J (1998) 2.10
Stimulation of the caudal zona incerta is superior to stimulation of the subthalamic nucleus in improving contralateral parkinsonism. Brain (2006) 2.07
The natural history of spinocerebellar ataxia type 1, 2, 3, and 6: a 2-year follow-up study. Neurology (2011) 2.06
Explicit and implicit neural mechanisms for processing of social information from facial expressions: a functional magnetic resonance imaging study. Hum Brain Mapp (2000) 2.04
Analysis of 1071 gift procedures--the case for a flexible approach to treatment. Lancet (1988) 2.03
Autonomic ganglionitis with severe hypertension, migraine, and episodic but fatal hypotension. Neurology (1996) 2.03
Cognitive planning deficit in patients with cerebellar atrophy. Neurology (1992) 2.03
Tolerance to the humoral and hemodynamic effects of caffeine in man. J Clin Invest (1981) 2.03
Murine B cell lymphopoiesis in long term culture. J Immunol Methods (1984) 1.98
Corticobasal degeneration and progressive supranuclear palsy share a common tau haplotype. Neurology (2001) 1.95
DNA synthesis in the elongating nondividing cells of the lentil epicotyl and its promotion by gibberellin. Plant Physiol (1966) 1.94
Lay diagnosis and health-care-seeking behaviour for chest pain in south Asians and Europeans. Lancet (1997) 1.94
Lewy bodies and response to tacrine in Alzheimer's disease. Lancet (1994) 1.94
Model system for plant cell biology: GFP imaging in living onion epidermal cells. Biotechniques (1999) 1.92
Prevalence of antigliadin antibodies in ataxia patients. Neurology (2003) 1.89
Comparative assessment of stimuli that release neuronal and adrenomedullary catecholamines in man. Circulation (1979) 1.88
What features improve the accuracy of clinical diagnosis in Parkinson's disease: a clinicopathologic study. 1992. Neurology (2001) 1.87
Inhibition of signal transduction by the Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin results in cytostasis and apoptosis. Cancer Res (2001) 1.86
Hypertensive cardiovascular damage in patients with primary autonomic failure. Lancet (2000) 1.86